Radiofrequency treatment of turbinate hypertrophy in subjects using continuous positive airway pressure: A randomized, double-blind, placebo-controlled clinical pilot trial

被引:99
|
作者
Powell, NB
Zonato, AI
Weaver, EM
Li, K
Troell, R
Riley, RW
Guilleminault, C
机构
[1] Stanford Univ, Dept Psychiat & Behav Sci, Stanford Sleep Disorders & Res Ctr, Sch Med, Stanford, CA 94305 USA
[2] Univ Washington, Sch Med, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA
[3] Dept Otolaryngol Head & Neck Surg, Sao Paulo, Brazil
关键词
temperature-controlled radiofrequency; turbinate hypertrophy; sleep-disordered breathing; CPAP; placebo-controlled; randomized trial; double-blind;
D O I
10.1097/00005537-200110000-00023
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objectives: To estimate the treatment effect of temperature-controlled radio-frequency (TCRF) reduction of turbinate hypertrophy in patients with sleep-disordered breathing (SDB) treated with nasal continuous positive airway pressure (CPAP), and to assess the impact of study design on this estimate. Study Design: Prospective, randomized, double-blind, placebo-controlled clinical pilot trial. Methods. Twenty-two CPAP-treated patients with SDB with turbinate hypertrophy were randomly assigned to either TCRF turbinate treatment (mean energy 415 +/- 37 J/turbinate; n = 17) or placebo control (n = 5). Changes in nasal obstruction were evaluated between pretreatment and 4 weeks post-treatment. The primary outcome assessed changes in the blinded examiners' findings of nasal obstruction on a visual analogue scale (VAS). Secondary outcomes included blinded patients' and unblinded examiner assessments of nasal obstruction (VAS), nightly CPAP use, adherence, and tolerance, along with sleepiness and general health status scales. The treatment group findings were subtracted from the changes in the placebo group to yield treatment effect. Results: The primary outcome treatment effect by VAS was -0.9 cm. (95% confidence interval [CI], -2.4, 0.7), and beyond the placebo effect of -1.5 cm. (95% CI: -3.4, 0.3). The secondary treatment effect of the unblinded examiner was -3.0 cm (95% CI, -4.9, -1.1). A beneficial treatment effect was also seen on every secondary outcome except general health status, but only self-reported CPAP adherence (P = .03) was statistically significant. Conclusions: TCRF turbinate treatment appears to benefit nasal obstruction and CPAP treatment for SDB. Placebo control and double blinding are critical for establishing the true treatment effect. A future definitive trial is feasible to establish statistical significance of these findings. Key Words. Temperature-controlled radiofrequency, turbinate hypertrophy, sleep-disordered breathing, CPAP, placebo-controlled, randomized trial, double-blind.
引用
收藏
页码:1783 / 1790
页数:8
相关论文
共 50 条
  • [1] Atovaquone for treatment of COVID-19: A prospective randomized, double-blind, placebo-controlled clinical trial
    Jain, Mamta K.
    De Lemos, James A.
    McGuire, Darren K.
    Ayers, Colby.
    Eitson, Jennifer L.
    Sanchez, Claudia L.
    Kamel, Dena
    Meisner, Jessica A.
    Thomas, Emilia V.
    Hegde, Anita A.
    Mocherla, Satish
    Strebe, Joslyn K.
    Li, Xilong
    Williams, Noelle S.
    Xing, Chao
    Ahmed, Mahmoud S.
    Wang, Ping
    Sadek, Hesham A.
    Schoggins, John W.
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [2] A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Rett Syndrome
    Glaze, Daniel G.
    Neul, Jeffrey. L.
    Percy, Alan
    Feyma, Tim
    Beisang, Arthur
    Yaroshinsky, Alex
    Stoms, George
    Zuchero, David
    Horrigan, Joseph
    Glass, Larry
    Jones, Nancy E.
    PEDIATRIC NEUROLOGY, 2017, 76 : 37 - 46
  • [3] Topical pentoxifylline for pressure ulcer treatment: a randomised, double-blind , placebo-controlled clinical trial
    Najafi, Elham
    Ahmadi, Motahareh
    Mohammadi, Mostafa
    Beigmohammadi, Mohammad-Taghi
    Heidary, Zinat
    Vatanara, Alireza
    Khalili, Hossein
    JOURNAL OF WOUND CARE, 2018, 27 (08) : 495 - 502
  • [4] A double-blind, randomized, placebo-controlled trial of macrolide in the treatment of chronic rhinosinusitis
    Wallwork, B
    Coman, W
    Mackay-Sim, A
    Greiff, L
    Cervin, A
    LARYNGOSCOPE, 2006, 116 (02) : 189 - 193
  • [5] Randomized, placebo-controlled, double-blind trial of Swedish snus for smoking reduction and cessation
    Gordana Joksić
    Vera Spasojević-Tišma
    Ruza Antić
    Robert Nilsson
    Lars E Rutqvist
    Harm Reduction Journal, 8
  • [6] Randomized, placebo-controlled, double-blind trial of Swedish snus for smoking reduction and cessation
    Joksic, Gordana
    Spasojevic-Tisma, Vera
    Antic, Ruza
    Nilsson, Robert
    Rutqvist, Lars E.
    HARM REDUCTION JOURNAL, 2011, 8
  • [7] A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia
    Chappell, Amy S.
    Bradley, Laurence A.
    Wiltse, Curtis
    Detke, Michael J.
    D'Souza, Deborah N.
    Spaeth, Michael
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2008, 1 : 91 - 102
  • [8] A 12-Week Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Topiramate for the Treatment of Compulsive Buying Disorder
    de Mattos, Cristiana
    Kim, Hyoun S.
    Marasaldi, Renata F.
    Requiao, Marinalva G.
    de Oliveira, Elen Cristina
    Filomensky, Tatiana
    Tavares, Hermano
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2020, 40 (02) : 186 - 190
  • [9] Topical heparin for the treatment of acute superficial phlebitis secondary to indwelling intravenous catheter A double-blind, randomized, placebo-controlled trialA double-blind, randomized, placebo-controlled trial
    M. Villardell
    D. Sabat
    J. A. Arnaiz
    M. J. Bleda
    J. M. Castel
    J. R. Laporte
    C. Vallvé
    European Journal of Clinical Pharmacology, 1999, 54 : 917 - 921
  • [10] A randomized, placebo-controlled, double-blind trial of ondansetron in renal itch
    Murphy, M
    Reaich, D
    Pai, P
    Finn, P
    Carmichael, AJ
    BRITISH JOURNAL OF DERMATOLOGY, 2003, 148 (02) : 314 - 317